CN102552852B - Pharmaceutical composition and use thereof - Google Patents
Pharmaceutical composition and use thereof Download PDFInfo
- Publication number
- CN102552852B CN102552852B CN201210024378.6A CN201210024378A CN102552852B CN 102552852 B CN102552852 B CN 102552852B CN 201210024378 A CN201210024378 A CN 201210024378A CN 102552852 B CN102552852 B CN 102552852B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- group
- rat
- weight portion
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of medicine and especially relates to a pharmaceutical composition and a use thereof. The pharmaceutical composition has effects of reducing blood fat and blood sugar. The pharmaceutical composition comprises herb of spanishneedles, berberine, red sage root, pseudo-ginseng, stiff silkworm powder, rhizoma atractylodis, dry ginger and cassia bark. A result of a pharmacodynamical experiment shows that the pharmaceutical composition has good effects of reducing blood fat and blood sugar.
Description
Technical field
The invention belongs to medical technical field, the pharmaceutical composition that be specifically related to have blood sugar lowering, blood fat reducing etc. acts on.
Background technology
Diabetes are commonly encountered diseases, frequently-occurring disease, and its number of patients is just along with the change of the raising of living standards of the people, the aging of population, life style and improving of diagnostic techniques and increase sharply.And prolonged illness can cause multisystem infringement, cause the chronic progressive external pathological changes of the tissues such as eye, kidney, nerve, heart, blood vessel, cause functional defect and exhaustion.Diabetes spp is in the traditional Chinese medical science " diabetes " category.Chinese medicine thinks that the etiology and pathogenesis of diabetes is mainly that eating and drinking without temperance, disorder of emotion, labor are wanted excessively, innate deficiency etc., and causing cloudy body fluid deficiency consumption, scorching inclined to one side Sheng, the deficiency of YIN be this, scorching for marking, and as protracted inflammation, can cause deficiency of both QI and YIN or deficiency of both YIN and YANG; Blood stasis, damp and hot, phlegm-damp, diseases caused by retention of fluid are its common pathological products, and these pathological products can become new paathogenic factor again, further increase the weight of the diabetes state of an illness.
Diabetes can be involved trunk and blood capillary with PD, merge as many complication such as hypertension, coronary heart disease, retinopathy, diabetic foot, serious threat human health and life.Wherein diabetes merge dyslipidemia, are to cause one of fatty liver, atherosclerosis, the pathogenetic Major Risk Factors of coronary heart disease cerebrovascular.Diabetes merge disorders of lipid metabolism and more and more obtain academia attention, and the international molecule diabetes of Second Committee in 2000 meeting even proposes " glycolipid is sick " and says, is intended to emphasize the critical role of disorders of lipid metabolism in sugared evolution.Development along with Chinese medicine, the understanding that merges dyslipidemia for diabetes is day by day goed deep into, at present Chinese medicine is used single medicinal material and extract thereof, compound treatment primary disease more, compare with Western medicine and can not only significantly regulate blood fat, can also regulate the Novel presentation of body simultaneously, and mostly have no side effect, obtained clinically good efficacy.Therefore, the research of the dyslipidemia of TCM treatment of diabetes merging from now on should be under instruction of Chinese Medicine theory, establish unified differentiation of symptoms and signs for classification of syndrome standard, make great efforts to absorb modern medicine to abnormal newest research results, the two is combined effectively, improve the science of scientific research and design, strengthen the credibility of clinical research, Therapeutic Method to own effective single medicine and compound recipe further screens, strive for accomplishing that curative effect is lasting, reliable, make TCM Treatment of Diabetes merge dyslipidemia and obtain larger achievement.
Summary of the invention
For these reasons, applicant be take theory of Chinese medical science as basis, in conjunction with clinical experience, Herba Bidentis Bipinnatae, berberine, Radix Salviae Miltiorrhizae, Radix Notoginseng, Bombyx Batryticatus powder, Rhizoma Atractylodis, Rhizoma Zingiberis and Cortex Cinnamomi are carried out to organic compatibility, obtain new pharmaceutical composition, pharmacological testing shows, pharmaceutical composition of the present invention has good blood fat reducing and hypoglycemic effect.
The present invention is achieved through the following technical solutions.
, pharmaceutical composition is comprised of following raw material: Herba Bidentis Bipinnatae, berberine, Radix Salviae Miltiorrhizae, Radix Notoginseng, Bombyx Batryticatus powder, Rhizoma Atractylodis, Rhizoma Zingiberis and Cortex Cinnamomi.
Preferred pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-10 weight portion, berberine 0.1-1 weight portion, Radix Salviae Miltiorrhizae 3-10 weight portion, Radix Notoginseng 1-5 weight portion, Bombyx Batryticatus powder 0.5-5 weight portion, Rhizoma Atractylodis 1-8 weight portion, Rhizoma Zingiberis 1-8 weight portion, Cortex Cinnamomi 0.5-5 weight portion.
Preferred pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 5-7 weight portion, berberine 0.4-0.5 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion, Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion, Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
Preferred pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion, Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 2-3 weight portion, Rhizoma Atractylodis 5-7 weight portion, Rhizoma Zingiberis 2-3 weight portion, Cortex Cinnamomi 0.8-1 weight portion.
Preferred pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 2-3 weight portion, berberine 0.1-0.2 weight portion, Radix Salviae Miltiorrhizae 4-5 weight portion, Radix Notoginseng 1-2 weight portion, Bombyx Batryticatus powder 0.8-1 weight portion, Rhizoma Atractylodis 2-3 weight portion, Rhizoma Zingiberis 5-7 weight portion, Cortex Cinnamomi 2-3 weight portion.
Pharmaceutical composition described above is that raw material is prepared into dosage forms such as comprising oral formulations.
The application of aforementioned pharmaceutical compositions in preparation treatment high blood cholesterol drug.
The application of aforementioned pharmaceutical compositions in the medicine of preparation treatment diabetes.
Oral formulations described above includes but not limited to tablet, capsule, granule, oral liquid, mixture or pill.
One, pharmacological testing research
The following test of the present invention is on test of many times basis, the test that claimed technical scheme is carried out according to the present invention.
1 experiment material
1.1 tested medicine and control drug
Tested medicine: in Table 1:
Preparation method: said medicine (except berberine) is added to 8 times of water extraction of medical material weight 2 hours, after extracting solution concentrate drying, mix homogeneously with berberine, standby.Berberine: berberine hydrochloride (Guangdong Huanan Pharmaceutical Co., Ltd).
Control drug: Rosiglitazone Maleate Tablets, GlaxoSmithKline PLC (Tianjin) company limited (lot number: 08070167).
1.2 laboratory animal
SPF level male SD rat (80-120g), is purchased from Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center, and credit number is SCXK (Guangdong) 2003-0001.
1.3 key instruments and reagent
Electronic balance (U.S. Shuan Jie Group Co.,Ltd); BS110S electronic balance (Sartorius company); Hot water constant temperature groove (Shanghai Yiheng Scientific Instruments Co., Ltd); Digital electronic clinical thermometer (Fuda, Shenzhen health Industrial Co., Ltd.); TG-16W desk centrifuge (Changsha Xiang Zhi centrifuge company limited); RT-2100C microplate reader (east, the Five continents, Beijing development in science and technology company limited); The automatic non-invasive blood pressure test macro in clematis stem road (IITC65-12Manual Scanner, IITC INC., USA); The accurate pipettor of big dragon; Vortex mixer (Shanghai Qi Te Analytical Instrument Co., Ltd);-80 ℃ of ultra cold storage freezers (SANYO).
Streptozotocin STZ (
s0130-500MG, lot number 1000712061); Citric acid and sodium citrate (Sigma C1909); Roche
superior blood glucose meter (ACCU-CHZK) and blood sugar test paper, be all purchased from company of Switzerland Roche Group; Anhydrous glucose (lot number 20080905), is purchased from Tianjin good fortune chemical reagent factory in morning; Glucose assays test kit (lot number 20100502), is purchased from glad biotechnology research institute of Shanghai section; T-CHOL is measured test kit (lot number 090304), and triglyceride determination test kit (lot number 2010002), is all purchased from Changchun Hui Li Bioisystech Co., Ltd; Flesh/hepatic glycogen test kit (lot number 20101126), free fatty (lot number 20101213) is all purchased from Nanjing and builds up Bioengineering Research Institute.
2 experimental techniques
2.1 reagent preparations
0.1mol/L citric acid one sodium citrate buffer solution compound method: take 2.10g citric acid, be dissolved in 100ml without dissolving in ion sterilized water, be made into 0.1mol/L citric acid solution A.Take 2.94g sodium citrate, be dissolved in 100ml without in ion sterilized water, be made into 0.1mol/L sodium citrate solution B.In A liquid: B liquid mixes and is made into citric acid-sodium citrate buffer in 1: 1.2 ratio.PH meter is measured pH value, and adjusting pH is 4.2-4.5, and 4 ℃ of cold preservations are standby.
STZ solution preparation method: take a certain amount of STZ, with 0.1mol/L citric acid-sodium citrate buffer, be mixed with 2% concentration, adjust pH to 4.20 left and right, operation is all carried out in ice bath.
2.2 animal model
Rat adaptability was fed after 3 days, randomly drawed 10 rats and fed to normal diet as Normal group.Remaining rat gives high lipid food, and feeding amount is not limit.All rats are freely drunk distilled water, room temperature 22-28 ℃, and natural lighting, weighs weekly.The rat of high fat diet group gives sunflower seed every other day, feeds continuously the body weight of set time monitoring rat weekly during nursing 12 weeks.Feed after 12 weeks, will not become fat rat to carry out the modeling of STZ lumbar injection, fasting be can't help water and is spent the night, the STZ citrate buffer solution of lumbar injection 25mg/kg, the citrate buffer solution of Normal group lumbar injection same volume.After 7 days, overnight fasting, tail venous blood sampling is surveyed fasting glucose, and rat whole blood blood glucose value >=11.0mmol/L, is classified as diabetes model.
2.3 feed formula
High lipid food formula: 50% normal diet, 15% casein, 5% Semen arachidis hypogaeae, 10% yolk powder, 12% Adeps Sus domestica, 5% sucrose, 1% Oleum Sesami, 2% Sal, 10/50kg of cod-liver oil.Feedstuff is processed by Guangdong Medical Lab Animal Center.
Normal diet: provided by Beijing section Australia feed corporation,Ltd that pulls together.
2.4 grouping administrations
Obese rat is divided into five groups at random, i.e. 1. model group, and 2. positive drug Avandia group, 3. prescription 1, and 4. prescription 2, and 5. prescription 3; Dosage (in Table 2) is definite according to " pharmacological experimental methodology " formula, and the dosage of compound medicine and Avandia is all equivalent to 5 times of people's consumption, and formula is as follows:
Rat dosage (mg/kg)=people's dosage (mg/kg) * 90% * (body weight for humans/Mus body weight)
1/3
Table 2 each treated animal number of elements and dosage
| Group | N | Dosage |
| Normal group | 10 | 10ml/kgd distilled water |
| Model group | 14 | 10ml/kgd distilled water |
| Avandia group | 15 | 0.3mg/kg·d |
| Prescription 1 | 14 | 1.665g/kg·d |
| Prescription 2 | 14 | 1.565g/kg·d |
| Prescription 3 | 15 | 1.665g/kg·d |
Medicaments compound decocts once every day, successive administration 7 weeks.
2.5 experimental index are measured
Every day observation experiment rat state;
Survey weekly body weight one time, a 24h food ration;
Within every two weeks, do a metabolism, survey food ration amount of drinking water, voided volume, feces volume and anus temperature;
Blood serum sample preparation: administration is after 7 weeks, fasting 12h, the rat of first weighing, with etherization experimental rat, eye socket venous blood sampling 4ml, standing 30min afterwards, the centrifugal 10min separation of serum of 3500r/min, is sub-packed in blood serum sample in the PCR pipe of 12 parts of 0.2ml, each 100 μ l,-80 ℃ save backup to detect each index, and each index is measured according to product description.
Tissue sample preparation and preservation: when experiment finishes, get liver, left kidney, normal saline flushing, filter paper blots weighs, and calculates organ coefficient; Get hepatomegaly leaf four segments and encase with tinfoil ,-80 ℃ of freezing confessions are measured FFA and hepatic glycogen, get rat thigh skeletal muscle and encase with tinfoil, and-80 ℃ freezing for measuring muscle glycogens.By the heart, liver, kidney, pancreas, with 10% formalin, to fix, HE dyeing, with Zeiss (Axiostar Plus) optical microphotograph Microscopic observation.
Body fat ratio: weigh before putting to death animal, put to death after animal, get epididymis other fat and bilateral perirenal fat and weigh, because fat on mesentery is more difficult separated clean from intestinal, easily cause resultant error, therefore this experiment interior fat does not count.Body fat ratio=(the other fat weight+perirenal fat weight of epididymis)/rat body weight * 100%.
Liver tissue homogenate's preparation: take the frozen hepatic tissue of 200mg, add 2ml PBS, homogenate in ice bath, the centrifugal 20min of 3500r/min, carefully collects supernatant, detects TG and the FFA content of hepatic tissue with biochemical reagents box.
2.6 statistical method
Use SPSS16.0 statistical software to carry out data analysis and figure output.Data are all used mean ± standard
represent.Each factor adopts single factor variance and t check.
3 experimental results
3.1 overview situations
The rats in normal control group mental status is good, and fur is glossy, and body weight rises continually and steadily.Type 2 diabetes mellitus rat is during administration, and body weight gain is slow, bradykinesia, and slow movement, fur tarnishes.Prescription 3, Avandia group respectively has one because of the too high death of blood glucose.Diabetes rat is except prescription 2, and each group has 1-2 only because of the otitis media death of becoming thin.
3.2 diabetes rats " three-many-one-little " are evaluated
During administration, there is significantly " polydipsia, polyphagia, polyuria " symptom in diabetes rat, and the food ration of administration group rat is substantially lower than model group, and amount of drinking water and urine amount and model group difference are little, and anus temperature is a little more than model group, but the equal not statistically significant of difference.
Body weight change situation during 3.3 administrations
During administration: the body weight gain of model group is slow compared with administration group and normal group, but not statistically significant.Administration surrounding, the body weight compared with normal group of model group obviously reduces (P < 0.05); Prescription 2 is faster than other diabetes rats with the body weight gain of Avandia group, and body weight gain trend and the model group of prescription 1 and prescription 3 are more or less the same, all not statistically significant (in Table 3).
The body weight change of experimental rat during table 3 administration
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
The change of blood sugar of 3.4 experimental rats
The fasting blood glucose level of experimental rat before and after table 4 administration (
mmol/L)
| Group | N | Before administration | After administration |
| Normal group | 8 | 5.9±0.35 | 5.4±0.20 |
| Model group | 8 | 14.4±2.39** | 20.7±3.66** |
| Avandia group | 8 | 14.7±2.30 | 12.8±2.56# |
| Prescription 1 | 8 | 12.7±2.39 | 20.1±5.42 |
| Prescription 2 | 10 | 13.5±2.99 | 12.6±2.97# |
| Prescription 3 | 8 | 14.1±2.26 | 18.1±4.88 |
Note: with normal group comparison: * * represents P < 0.01; Represent P < 0.05 with model group comparison: #.
Before administration, the fasting blood glucose level of diabetes rat (FPG) is apparently higher than normal group (P < 0.01).After modeling 8 weeks, model group was still apparently higher than normal group (P < 0.01); With model group comparison, 8 weeks rear blood glucose of prescription 2 treatment has obvious decline (P < 0.05).
The organ coefficient of experimental rat after 3.5 treatments
Table 5 shows, normal rats liver, kidney perusal color are scarlet, smooth surface, and the liver surface of diabetes rat has slight or obvious lipochondrion shape, and kidney volume is bigger.The Kidney coefficients of diabetes rat has been compared utmost point significant difference (P < 0.05 or P < 0.01) with normal group, liver coefficient is bigger than normal, but no significant difference.The dirty coefficient of device of administration group is compared no significant difference with model group.
The organ coefficient of table 5 experimental rat
| Group | N | Kidney coefficients (%) | Liver coefficient (%) | Body fat is than (%) |
| Normal group | 8 | 0.30±0.03 | 2.38±0.22 | 1.91±0.61 |
| Model group | 8 | 0.39±0.05* | 2.93±0.59 | 2.22±0.54 |
| Avandia group | 8 | 0.39±0.06 | 3.02±0.59 | 2.60±0.62 |
| Prescription 1 | 8 | 0.42±0.04 | 3.39±0.37 | 1.87±0.52 |
| Prescription 2 | 10 | 0.40±0.06 | 2.99±0.35 | 1.42±0.40 |
| Prescription 3 | 8 | 0.40±0.08 | 3.13±0.41 | 2.01±0.93 |
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
3.6 impacts on hepatic glycogen and muscle glycogen
Table 6 shows, the hepatic glycogen content compared with normal group of model group and prescription 1 obviously raise (P < 0.01); With model contrast, the hepatic glycogen content of administration group all has reduction, especially with Avandia group the most obviously (P < 0.05).Compare with normal group, the content of the muscle glycogen of diabetes rat all has rising, and the muscle glycogen content of administration group all has reduction compared with model group, but the equal not statistically significant of difference.
Hepatic glycogen and the muscle glycogen level of experimental rat after table 6 treatment
| Group | N | Hepatic glycogen (mg/g) | Muscle glycogen (mg/g) |
| Normal group | 8 | 6.49±3.22 | 1.33±0.28 |
| Model group | 8 | 32.18±12.35** | 2.03±0.56 |
| Avandia group | 8 | 13.86±7.55# | 1.77±0.65 |
| Prescription 1 | 8 | 40.23±6.61 | 1.50±0.46 |
| Prescription 2 | 10 | 17.42±9.99 | 1.79±0.33 |
| Prescription 3 | 8 | 16.25±12.45 | 1.91±0.64 |
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
3.7 impacts on lipid metabolism index
TG, the FFA level of experimental rat serum TG ,TCJi liver tissue homogenate after table 7 treatment
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
As can be seen from Table 7, with normal group contrast, the TG content of model group serum, hepatic tissue obviously raise (P < 0.01).With model group contrast, the serum TG of administration group and TC content have no remarkable reduction; But hepatic tissue TG, FFA all have obvious decline, with the flat successful of prescription 2 (P < 0.01).
Two, 2 couples of INS of prescription, TNF-α, the impact of endotoxin and cyclic nucleotide
1 material
1.1 sample
-80 ℃ of frozen serum of normal group, model group, Avandia group and prescription 2
1.2 key instruments and reagent
RT-2100C microplate reader (east, the Five continents, Beijing development in science and technology company limited);
The accurate pipettor (10 μ l-100 μ l, 100 μ l-1000 μ l) of big dragon;
Vortex mixer (Shanghai Qi Te Analytical Instrument Co., Ltd);
-80 ℃ of ultra cold storage freezers (SANYO);
Hot water constant temperature groove (Shanghai Yiheng Scientific Instruments Co., Ltd);
ELISA test kit (INS, TNF-α, ET, cAMP, cGMP) is all purchased from R& D company.
2 experimental techniques
2.1 sample detection
According to ELISA test kit description to normal group, model group, Avandia group and prescription 2 rat blood serum INS, TNF-α, ET, cAMP, the indexs such as cGMP detect.
2.2 statistical method
Use OriginPro8.1 statistical software to carry out data analysis.Data are all used mean ± standard deviation
represent, each factor adopts single factor variance and t check.
3 results
3.1 impacts on diabetes rat serum fasting glucose (FPG), insulin (INS) and insulin sensitivity index (ISI)
As seen from Table 8, with normal group contrast, FPG and the ISI of model group significantly reduces (P < 0.01).With model group contrast, the serum FPG level of prescription 2 is significantly lower than model group (P < 0.05), but INS, the ISI value of 2 groups of prescriptions are inclined to one side and model group comparing difference not statistically significant.
Table 8 is respectively organized the rear serum FPG of rat treatment, INS, the value of ISI
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
The TNF-α of 3.2 pairs of diabetes rat serum and the content influence of ET
As seen from Table 9, with normal group contrast, the Serum Level of Tumor Necrosis Factor-α of model group (TNF-α) and endotoxin (ET) level significantly raise (P < 0.01).With model group contrast, the TNF-α level of prescription 2 obviously reduces (P < 0.05), and Serum ET level is on the low side, but difference not statistically significant.
Table 9 is respectively organized the rear TNF-α of rat treatment and ET level
| N | TNF-α(mmol/L) | ET(ngl/L) |
| (ng/L) | (EU/L) | ||
| Normal group | 8 | 2.26±0.47 | 3.03±0.53 |
| Model group | 9 | 9.13±2.19** | 5.46±0.85** |
| Avandia group | 9 | 6.98±1.05 | 6.50±1.33 |
| Prescription 2 | 9 | 5.89±2.34# | 4.92±1.02 |
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
3.3 couples of obese rat serum cAMP, the impact of cGMP level and cAMP/cGMP
Table 10 is respectively organized the rear cAMP of rat treatment, cGMP level and cAMP/cGMP ratio
Note: represent P < 0.05 with normal group comparison: *, * * represents P < 0.01; Represent P < 0.05 with model group comparison: #, ## represents P < 0.01.
Table 10 result shows, contrasts with normal group, and model group serum cAMP level, cGMP level and cAMP/cGMP ratio decline, but difference not statistically significant.With model group contrast, the cGMP level of prescription 2 significantly raises (P < 0.05), and cAMP/cGMP ratio is higher than model group, but difference not statistically significant.
4 discuss
4.1 couples of FPG, the impact of INS and ISI
The part beta Cell of islet of STZ injury rats, hypoinsulinism causes blood sugar increasing.In this result of study, the blood sugar increasing of display model group is due to serum insulin relative deficiency and the low coefficient result of insulin sensitivity, in conjunction with sick inspection, prescription 2 part islets of langerhans hypertrophy, illustrate that this compound recipe may be by improving islet function to promote insulin secretion, thereby reduction blood glucose, improves insulin resistant.
4.2 impacts on TNF-α and ET
TNF-α is the mononuclear phagocyte of activation and a kind of cytokine of adipose cell secretion, has biological activity widely.TNF-α is mainly by different Pathway Activation color/threonine (Ser/Thr) kinases, and the conduction of interfere with insulin signal affects signal transduction pathway after receptor, finally causes peripheral insulin resistance [142].In this test, the TNF-α of diabetes rat is higher than normal rat, and the TNF-α of prescription 2 obviously reduces compared with model group, and prompting heat clearing away compound recipe can reduce the generation of TNF-α, reduces inflammatory reaction, improves insulin resistant.
In this research, the horizontal compared with normal group of the serum endotoxin of diabetes rat significance raises, the serum endotoxin of testing obese rat is above high, this prompting rat through high lipid food cause fat the reason of fat opposing be possible due to body in intestinal microflora kind more, a large amount of consumed energies; The level of endotoxin of prescription 2 is on the low side in model group, and prompting prescription 2 may have the endotoxic ability of removing to play anti inflammatory detoxication effect.
4.3 couples of cAMP, the impact of cGMP level and cAMP/cGMP
Different pattern of syndrome person cyclic nucleotides change certain rule, can assist Syndrome Differentiation of Traditional Chinese Medicine.The cAMP of model group rat in this research, cGMP level and cAMP/cGMP are all lower than normal rat, and may there is intense heat due to deficiency of YIN type in prompting diabetes rat, and diabetes rat may improve basal metabolism by rising cAMP/cGMP ratio after prescription 2 treatments.
In a word, prescription 2 can suppress blood glucose in diabetic rats and hepatic glycogen raises, and improves TG and the FFA level of liver, improves carbohydrate tolerance, alleviates the lesion degree of the heart, liver and pancreas, lowers proinflammatory factor and level of endotoxin.This diabetes rat Long-term High-fat high-carbonhydrate diet, sugar can heat-dissipating, raw expectorant, and it is greasy stagnant that fat can heat-dissipating, property is held concurrently, therefore high glucose and high fat belongs to pyretic toxicity, expectorant poison, turbid poison, existing in blood is ecchymosis.Many experiments and clinical data all point out diabetes often to exist cell infiltration and cytokine, inflammatory cytokine levels to rise in recent years.And inflammatory factor belongs to the category of Chinese medicine " poison of interior life ".In conjunction with modern clinic, think that diabetes discuss from " poison " modern pathophysiological basis and the free radical toxicity its pathogenic process, inflammatory cytokine toxicity and the high glucose and high fat toxicity controlled closely related.In this research, prescription of the present invention forms take Herba Bidentis Bipinnatae, berberine as main, research report Herba Bidentis Bipinnatae has blood sugar lowering, blood fat reducing, anti-inflammatory and analgesic effect, berberine has blood fat, the blood sugar lowering of tune, resists myocardial ischemia, suppresses the pharmacological actions such as myocardial fibrosis, blood pressure lowering, antiplatelet, therefore we are having a significant effect aspect reduction blood glucose, and can improve liver lipid metabolism.
Three, Preparation Example
Embodiment 1
Pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 2g, berberine 0.2g, Radix Salviae Miltiorrhizae 4g, Radix Notoginseng 2g, Bombyx Batryticatus powder 0.6g, Rhizoma Atractylodis 3g, Rhizoma Zingiberis 2g, Cortex Cinnamomi 0.75g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 2
Pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 9g, berberine 1g, Radix Salviae Miltiorrhizae 8g, Radix Notoginseng 4g, Bombyx Batryticatus powder 4g, Rhizoma Atractylodis 7g, Rhizoma Zingiberis 6g, Cortex Cinnamomi 4g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 3
Pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 6g, berberine 0.4g, Radix Salviae Miltiorrhizae 6g, Radix Notoginseng 2g, Bombyx Batryticatus powder 3g, Rhizoma Atractylodis 5g, Rhizoma Zingiberis 4g, Cortex Cinnamomi 0.8g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 4
Herba Bidentis Bipinnatae 600g, berberine 45g, Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g, Bombyx Batryticatus powder 90g, Rhizoma Atractylodis 250g weight portion, Rhizoma Zingiberis 250g, Cortex Cinnamomi 90g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 5
Pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 250g, berberine 15g, Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g, Bombyx Batryticatus powder 245g, Rhizoma Atractylodis 550g, Rhizoma Zingiberis 250g, Cortex Cinnamomi 90g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Embodiment 6
Pharmaceutical composition is comprised of the raw material of following weight portion: Herba Bidentis Bipinnatae 260g, berberine 15g, Radix Salviae Miltiorrhizae 460g, Radix Notoginseng 140g, Bombyx Batryticatus powder 85g, Rhizoma Atractylodis 245g, Rhizoma Zingiberis 650g, Cortex Cinnamomi 270g.
Said medicine is that raw material is prepared into tablet, capsule, granule, oral liquid, mixture or pill.
Described embodiment includes but not limited to above-mentioned.
Claims (5)
1. a pharmaceutical composition, is characterized in that: pharmaceutical composition is comprised of following raw material: Herba Bidentis Bipinnatae 6.00g, berberine 0.48g, Radix Salviae Miltiorrhizae 4.50g, Radix Notoginseng 1.50g, Bombyx Batryticatus powder 0.90g, Rhizoma Atractylodis 2.25g, Rhizoma Zingiberis 2.25g, Cortex Cinnamomi 0.90g.
2. a kind of pharmaceutical composition according to claim 1 is prepared into oral formulations.
3. the application of a kind of pharmaceutical composition of stating according to claim 1 office in preparation treatment high blood cholesterol drug.
4. the application of a kind of pharmaceutical composition according to claim 1 in the medicine of preparation treatment diabetes.
5. a kind of pharmaceutical composition according to claim 2 is prepared into oral formulations, and wherein oral formulations comprises tablet, capsule, granule, oral liquid, mixture or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210024378.6A CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210024378.6A CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552852A CN102552852A (en) | 2012-07-11 |
| CN102552852B true CN102552852B (en) | 2014-01-15 |
Family
ID=46400305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210024378.6A Expired - Fee Related CN102552852B (en) | 2012-02-03 | 2012-02-03 | Pharmaceutical composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552852B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605354B (en) * | 2015-01-27 | 2016-06-01 | 广西大学 | A kind of shrimp claw plant health care nutrition powder and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316275A (en) * | 2000-04-04 | 2001-10-10 | 徐代科 | Antihypertensive medicinal pillow |
| CN102274482A (en) * | 2011-08-19 | 2011-12-14 | 张丙焕 | Chinese medicinal preparation for treating diabetes |
-
2012
- 2012-02-03 CN CN201210024378.6A patent/CN102552852B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1316275A (en) * | 2000-04-04 | 2001-10-10 | 徐代科 | Antihypertensive medicinal pillow |
| CN102274482A (en) * | 2011-08-19 | 2011-12-14 | 张丙焕 | Chinese medicinal preparation for treating diabetes |
Non-Patent Citations (4)
| Title |
|---|
| 中药肉桂降血糖、降血脂作用的研究进展;何岚等;《中国现代中药》;20080831;第10卷(第8期);全文 * |
| 中药食疗对肥胖2型糖尿病患者血糖及血脂的影响;曾英等;《广西医学》;20060228;第28卷(第2期);全文 * |
| 何岚等.中药肉桂降血糖、降血脂作用的研究进展.《中国现代中药》.2008,第10卷(第8期),第8-11页. |
| 曾英等.中药食疗对肥胖2型糖尿病患者血糖及血脂的影响.《广西医学》.2006,第28卷(第2期),第199-201页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552852A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alarcon-Aguilar et al. | Acute and chronic hypoglycemic effect of Ibervillea sonorae root extracts-II | |
| Zhen et al. | Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats | |
| CN104705258B (en) | A kind of construction method of diet induced insulin resistant model and application | |
| Chen et al. | Elucidating dosage-effect relationship of different efficacy of rhubarb in constipation model rats by factor analysis | |
| Wang et al. | Semi-bionic extraction of compound turmeric protects against dextran sulfate sodium-induced acute enteritis in rats | |
| CN102349941A (en) | Traditional Chinese medicine composition for relieving fatigue and improving anoxia endurance and preparation method thereof | |
| Bhaskarachary et al. | Natural bioactive molecules with antidiabetic attributes: insights into structure–activity relationships | |
| CN102614267A (en) | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof | |
| CN104840777A (en) | Diabetes treating traditional Chinese medicine preparation and preparation method thereof | |
| CN102552852B (en) | Pharmaceutical composition and use thereof | |
| CN101234160B (en) | Fat-reducing and liver-protecting Chinese medicine preparation and preparation thereof | |
| Wu et al. | Moringa oleifera leaf supplementation relieves oxidative stress and regulates intestinal flora to ameliorate polycystic ovary syndrome in letrozole‐induced rats | |
| CN107073060B (en) | Aqueous extracts of cinnamon and astragalus | |
| CN101336974A (en) | Blood sugar and fat reducing traditional Chinese medicine with function of comprehensively adjusting body metabolism and preparation method thereof | |
| CN102526656A (en) | Medicament or health-care food composition for preventing or/and treating erythremia | |
| CN102526672B (en) | Traditional Chinese medicine composition, applications and preparation method | |
| Sairam et al. | Artocarpus altilis-mode of anti-hyperglycemic activity: elucidation by suitable in-vitro and ex-vivo techniques | |
| Yang et al. | The role of uterus mitochondrial function in high-fat diet-related adverse pregnancy outcomes and protection by resveratrol | |
| CN108309999B (en) | Pharmaceutical composition for preventing and treating atherosclerosis | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| Ping et al. | Research progress on the mechanism of TCM regulating intestinal microbiota in the treatment of DM mellitus | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN103432202B (en) | Method for extracting hypoglycemic substance from sculellaria barbata and application thereof | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140115 Termination date: 20200203 |